Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nutritional and Functional Changes in Heart Failure

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Texas A&M University
Sponsor:
Information provided by (Responsible Party):
Marielle PKJ Engelen, PhD, Texas A&M University
ClinicalTrials.gov Identifier:
NCT01787682
First received: February 4, 2013
Last updated: May 17, 2016
Last verified: May 2016

February 4, 2013
May 17, 2016
December 2012
February 2017   (final data collection date for primary outcome measure)
Net whole-body protein synthesis [ Time Frame: 0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 min post-meal ] [ Designated as safety issue: No ]
change in whole-body protein synthesis rate after intake of meal
Net whole-body protein synthesis [ Time Frame: 0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240 min post-meal ] [ Designated as safety issue: No ]
change in whole-body protein synthesis rate after intake of meal
Complete list of historical versions of study NCT01787682 on ClinicalTrials.gov Archive Site
  • Citrulline Rate of appearance [ Time Frame: Postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    plasma enrichment of citrulline
  • Glucose absorption [ Time Frame: 7 hours ] [ Designated as safety issue: No ]
    Recovery of 3-O-Methyl-D-glucose in the urine.
  • Gut permeability [ Time Frame: 7 hours ] [ Designated as safety issue: No ]
    recovery of rhamnose/lactulose in urine
  • Skeletal and respiratory muscle strength [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Difference in leg strength and fatigue, handgrip strength and fatigue, and inspiratory and expiratory pressure between heart failure patients and healthy controls.
  • Cognitive function [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Outcome of neuro-psychological tests in heart failure patients and healthy controls in relation to the tryptophan metabolism
  • Fatty acid digestion after feeding [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210 min post-meal ] [ Designated as safety issue: No ]
    Enrichment in palmitic acid and tripalmitin fatty acids in plasma
  • Protein digestion after feeding [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210, min post-meal ] [ Designated as safety issue: No ]
    Ratio enrichment free phenylalanine vs phenylalanine from protein spirulina
  • Arginine turnover rate [ Time Frame: postabsorptive state during 3 hours ] [ Designated as safety issue: No ]
    Arginine enrichment in plasma
  • Whole body collagen breakdown rate [ Time Frame: Postabsorptive state during 3 hours ] [ Designated as safety issue: No ]
    Hydroxyproline enrichment in plasma
  • Tryptophan turnover rate [ Time Frame: Postabsorptive state during 3 hours ] [ Designated as safety issue: No ]
    Tryptophan enrichment in plasma
  • Insulin response to feeding [ Time Frame: during 3 hours after feeding ] [ Designated as safety issue: No ]
    Acute change from postabsorptive state after intake of meal
  • Fat-free mass [ Time Frame: postabsorptive state during 15 min ] [ Designated as safety issue: No ]
    Characteristics of study subjects
  • Myofibrillar protein breakdown rate [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210 min post-meal ] [ Designated as safety issue: No ]
    3methylhistidine enrichment in plasma
  • Glycine rate of appearance [ Time Frame: Postabsorptive state during 3 hours ] [ Designated as safety issue: No ]
    glycine enrichment in plasma
  • Taurine turnover rate [ Time Frame: postabsorptive state during 3 hours ] [ Designated as safety issue: No ]
    enrichment of taurine in
  • Citrulline Rate of appearance [ Time Frame: Postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    plasma enrichment of citrulline
  • Glucose absorption [ Time Frame: 7 hours ] [ Designated as safety issue: No ]
    Recovery of 3-O-Methyl-D-glucose in the urine.
  • Gut permeability [ Time Frame: 7 hours ] [ Designated as safety issue: No ]
    recovery of rhamnose/lactulose in urine
  • Skeletal and respiratory muscle strength [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Difference in leg strength and fatigue, handgrip strength and fatigue, and inspiratory and expiratory pressure between heart failure patients and healthy controls.
  • Cognitive function [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Outcome of neuro-psychological tests in heart failure patients and healthy controls in relation to the tryptophan metabolism
  • Fatty acid digestion after feeding [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210,240 post-meal ] [ Designated as safety issue: No ]
    Enrichment in palmitic acid and tripalmitin fatty acids in plasma
  • Protein digestion after feeding [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210,240 post-meal ] [ Designated as safety issue: No ]
    Ratio enrichment free phenylalanine vs phenylalanine from protein spirulina
  • Arginine turnover rate [ Time Frame: postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    Arginine enrichment in plasma
  • Whole body collagen breakdown rate [ Time Frame: Postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    Hydroxyproline enrichment in plasma
  • Tryptophan turnover rate [ Time Frame: Postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    Tryptophan enrichment in plasma
  • Insulin response to feeding [ Time Frame: during 4 hours after feeding ] [ Designated as safety issue: No ]
    Acute change from postabsorptive state after intake of meal
  • Fat-free mass [ Time Frame: postabsorptive state during 15 min ] [ Designated as safety issue: No ]
    Characteristics of study subjects
  • Myofibrillar protein breakdown rate [ Time Frame: 0,15,30,45,60,75,90,105,120,150,180,210,240min post-meal ] [ Designated as safety issue: No ]
    3methylhistidine enrichment in plasma
  • Glycine rate of appearance [ Time Frame: Postabsorptive state during 2 hours ] [ Designated as safety issue: No ]
    glycine enrichment in plasma
Not Provided
Not Provided
 
Nutritional and Functional Changes in Heart Failure
Metabolic and Functional Changes in Relation to Nutritional Status in Chronic Heart Failure
Weight loss commonly occurs in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disorder (COPD), negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of weight loss in CHF and COPD patients but patients also have reductions in fat mass and bone density, independent of the severity of the disease state. The purpose of this cross-sectional study is to provide detailed insight in disease related gut function by obtaining information on gut permeability, digestion and absorption of glucose, fat and protein in CHF and COPD patients compared to matched healthy controls. This will provide required information that is necessary to implement new strategies to develop optimal nutritional regimen in CHF and COPD. The hypothesis is that CHF and COPD are related to decreased gut function and absorption, leading to decreased anabolic response. Second, this decreased nutritional status is linked to reduced muscle functioning and possibly decreased cognition. In addition, we will examine the effect of aging on by comparing gut function digestion and absorption of the CHF and COPD aged matched healthy controls to a group of young healthy subjects.
This study involves one test day of approximately 7-8 hours. On this test day subjects will ingest a sugar drink to assess gut permeability and gut function, and a protein meal to measure digestion/absorption and the anabolic response to food intake. Subjects will also receive a mixture of amino acids that are made a little heavier than normal, called stable isotopes. This stable isotopes is used to investigate protein behavior in the body (protein kinetics). Blood (100-120 ml in total) and urine samples will be collected over 7 hours.
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Chronic Heart Failure
  • Chronic Obstructive Pulmonary Disorder
Dietary Supplement: BOOST High Protein
Experimental: Boost High Protein
Boost high protein with added spirulina
Intervention: Dietary Supplement: BOOST High Protein
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
105
February 2018
February 2017   (final data collection date for primary outcome measure)

Inclusion criteria CHF subjects:

  • Ability to walk, sit down and stand up independently
  • Age 45 years or older
  • Ability to lie in supine or elevated position for 7 hours
  • Diagnosis of Chronic Heart Failure; under regular care by cardiologist
  • NYHA class II-IV
  • Reduced ejection fraction (<45%) assessed in the past 2 years
  • Clinically stable condition; no hospitalization 4 weeks preceding first study day
  • Willingness and ability to comply with the protocol

Inclusion criteria COPD subjects:

  • Ability to walk, sit down and stand up independently
  • Age 45 years or older
  • Ability to lie in supine or elevated position for 8 hours
  • Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: FEV1 < 70% of reference FEV1
  • Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 > 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day
  • Shortness of breath on exertion
  • Willingness and ability to comply with the protocol

Inclusion criteria healthy control subjects:

  • Healthy male or female according to the investigator's or appointed staff's judgment
  • Ability to walk, sit down and stand up independently
  • Age 45 years or older (older control group)
  • Age between 20-30 years old (young group)
  • Ability to lay in supine or elevated position for 7 hours
  • No diagnosis of CHF
  • Willingness and ability to comply with the protocol

Exclusion Criteria:

  • Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (healthy subjects only)
  • History of untreated metabolic diseases including hepatic or renal disorder
  • Presence of acute illness or metabolically unstable chronic illness
  • Presence of fever within the last 3 days
  • Body mass index >40 kg/m2 (healthy subjects only)
  • Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
  • Use of protein or amino acid containing nutritional supplements within 5 days of first study day
  • Current use of long-term oral corticosteroids (CHF only)
  • Use of short course of oral corticosteroids within 4 weeks preceding first study day
  • Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
  • (Possible) pregnancy
Both
45 Years and older   (Adult, Senior)
Yes
Contact: Marielle PKJ Engelen, PhD 979-2202282 mpkj.engelen@ctral.org
Contact: Fari T Koeman 9792195505 f.koeman@ctral.org
United States
 
NCT01787682
2012-0503
No
Not Provided
Not Provided
Marielle PKJ Engelen, PhD, Texas A&M University
Texas A&M University
Not Provided
Principal Investigator: Marielle PKJ Engelen, PhD Texas A&M Univeristy
Texas A&M University
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP